ADMA Biologics, Inc. (ADMA)
9.34
-0.14
(-1.48%)
USD |
NASDAQ |
Aug 28, 16:00
9.345
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Free Cash Flow : 116.22M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 116.22M |
| March 31, 2026 | 107.55M |
| December 31, 2025 | 27.50M |
| September 30, 2025 | 40.61M |
| June 30, 2025 | 65.61M |
| March 31, 2025 | 90.28M |
| December 31, 2024 | 110.10M |
| September 30, 2024 | 78.82M |
| June 30, 2024 | 66.12M |
| March 31, 2024 | 15.91M |
| December 31, 2023 | 3.819M |
| September 30, 2023 | -23.50M |
| June 30, 2023 | -51.39M |
| March 31, 2023 | -61.23M |
| December 31, 2022 | -73.42M |
| September 30, 2022 | -99.43M |
| June 30, 2022 | -98.97M |
| March 31, 2022 | -118.94M |
| December 31, 2021 | -125.88M |
| September 30, 2021 | -124.56M |
| June 30, 2021 | -135.09M |
| March 31, 2021 | -123.81M |
| December 31, 2020 | -114.73M |
| September 30, 2020 | -100.16M |
| June 30, 2020 | -99.02M |
| Date | Value |
|---|---|
| March 31, 2020 | -92.33M |
| December 31, 2019 | -80.01M |
| September 30, 2019 | -78.37M |
| June 30, 2019 | -65.54M |
| March 31, 2019 | -62.19M |
| December 31, 2018 | -64.77M |
| September 30, 2018 | -60.53M |
| June 30, 2018 | -58.07M |
| March 31, 2018 | -51.53M |
| December 31, 2017 | -39.95M |
| September 30, 2017 | -28.20M |
| June 30, 2017 | -22.58M |
| March 31, 2017 | -18.56M |
| December 31, 2016 | -18.34M |
| September 30, 2016 | -18.79M |
| June 30, 2016 | -16.79M |
| March 31, 2016 | -16.39M |
| December 31, 2015 | -15.44M |
| September 30, 2015 | -14.83M |
| June 30, 2015 | -16.01M |
| March 31, 2015 | -16.11M |
| December 31, 2014 | -17.03M |
| September 30, 2014 | -16.53M |
| June 30, 2014 | -14.91M |
| March 31, 2014 | -13.10M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Erasca, Inc. | -98.08M |
| Krystal Biotech, Inc. | 257.78M |
| Vericel Corp. | 61.66M |
| Emergent BioSolutions, Inc. | 85.90M |
| Exelixis, Inc. | 1.172B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 29.54M |
| Cash from Investing (Quarterly) | -2.256M |
| Cash from Financing (Quarterly) | -29.42M |
| Free Cash Flow Per Share (Quarterly) | 0.1184 |
| Free Cash Flow to Equity (Quarterly) | 27.85M |
| Free Cash Flow to Firm (Quarterly) | 29.86M |
| Free Cash Flow Yield | 5.19% |